XML 69 R54.htm IDEA: XBRL DOCUMENT v3.25.0.1
FAIR VALUE MEASUREMENTS - Additional Information (Details)
€ in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Mar. 04, 2021
EUR (€)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
In-process research and development impairments $ 4,180 $ 50 $ 2,700  
Write-off of finite-lived intangible asset 2,400 2,300 $ 1,800  
Manufacturing Assets        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Write-off   381    
Fair Value, Nonrecurring | Galapagos        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Write-off of finite-lived intangible asset   51    
Immunomedics, Inc. | Fair Value, Nonrecurring | Level 3 | Fair value        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Future royalties 900 1,200    
Immunomedics, Inc. | Fair Value, Nonrecurring | Level 3 | Carrying value        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Future royalties $ 1,100 $ 1,200    
Maximum        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Foreign currency derivative contract maturities (in months) 18 months      
Maximum | MYR        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent consideration liability | €       € 300